Cargando…

A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer

Background: The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). Methods: Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Jianmin, Li, Man, Dai, Kefan, Zuo, Bingyu, Guo, Jianhui, Zang, Lu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676246/
https://www.ncbi.nlm.nih.gov/pubmed/36419649
http://dx.doi.org/10.3389/pore.2022.1610643
_version_ 1784833550012383232
author Zeng, Jianmin
Li, Man
Dai, Kefan
Zuo, Bingyu
Guo, Jianhui
Zang, Lu
author_facet Zeng, Jianmin
Li, Man
Dai, Kefan
Zuo, Bingyu
Guo, Jianhui
Zang, Lu
author_sort Zeng, Jianmin
collection PubMed
description Background: The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). Methods: Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R “limma” package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. Results: A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. Conclusion: Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies.
format Online
Article
Text
id pubmed-9676246
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96762462022-11-22 A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer Zeng, Jianmin Li, Man Dai, Kefan Zuo, Bingyu Guo, Jianhui Zang, Lu Pathol Oncol Res Pathology and Oncology Archive Background: The aim of this study was to construct a glycolysis-related long noncoding RNA (lncRNA) signature to predict the prognosis of patients with gastric cancer (GC). Methods: Glycolysis-related genes were obtained from the Molecular Signatures Database (MSigDB), lncRNA expression profiles and clinical data of GC patients were obtained from The Cancer Genome Atlas database (TCGA). Furthermore, univariate Cox regression analysis, Least Absolute Shrinkage and Selection Operator (LASSO) and multivariate Cox regression analysis were used to construct prognostic glycolysis-related lncRNA signature. The specificity and sensitivity of the signature was verified by receiver operating characteristic (ROC) curves. We constructed a nomogram to predict the 1-year, 3-year, and 5-year survival rates of GC patients. Besides, the relationship between immune infiltration and the risk score was analyzed in the high and low risk groups. Multi Experiment Matrix (MEM) was used to analyze glycolysis-related lncRNA target genes. R “limma” package was used to analyze the mRNA expression levels of the glycolysis-related lncRNA target genes in TCGA. Gene set enrichment analysis (GSEA) was employed to further explore the biological pathways in the high-risk group and the glycolysis-related lncRNA target gene. Results: A prognostic signature was conducted based on nine glycolysis-related lncRNAs, which are AL391152.1, AL590705.3, RHOXF1-AS1, CFAP61-AS1, LINC00412, AC005165.1, AC110995.1, AL355574.1 and SCAT1. The area under the ROC curve (AUC) values at 1-year, 3-year, and 5-year were 0.765, 0.828 and 0.707 in the training set, and 0.669, 740 and 0.807 in the testing set, respectively. In addition, the nomogram could efficaciously predict the 1-year, 3-year, and 5-year survival rates of the GC patients. Then, we discovered that GC patients with high-risk scores were more likely to respond to immunotherapy. GSEA revealed that the signature was mainly associated with the calcium signaling pathway, extracellular matrix (ECM) receptor interaction, and focal adhesion in high-risk group, also indicated that SBSPON is related to aminoacyl-tRNA biosynthesis, citrate cycle, fructose and mannose metabolism, pentose phosphate pathway and pyrimidine metabolism. Conclusion: Our study shows that the signature can predict the prognosis of GC and may provide new insights into immunotherapeutic strategies. Frontiers Media S.A. 2022-11-07 /pmc/articles/PMC9676246/ /pubmed/36419649 http://dx.doi.org/10.3389/pore.2022.1610643 Text en Copyright © 2022 Zeng, Li, Dai, Zuo, Guo and Zang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pathology and Oncology Archive
Zeng, Jianmin
Li, Man
Dai, Kefan
Zuo, Bingyu
Guo, Jianhui
Zang, Lu
A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title_full A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title_fullStr A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title_full_unstemmed A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title_short A Novel Glycolysis-Related Long Noncoding RNA Signature for Predicting Overall Survival in Gastric Cancer
title_sort novel glycolysis-related long noncoding rna signature for predicting overall survival in gastric cancer
topic Pathology and Oncology Archive
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676246/
https://www.ncbi.nlm.nih.gov/pubmed/36419649
http://dx.doi.org/10.3389/pore.2022.1610643
work_keys_str_mv AT zengjianmin anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT liman anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT daikefan anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT zuobingyu anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT guojianhui anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT zanglu anovelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT zengjianmin novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT liman novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT daikefan novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT zuobingyu novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT guojianhui novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer
AT zanglu novelglycolysisrelatedlongnoncodingrnasignatureforpredictingoverallsurvivalingastriccancer